BTK Inhibitor Therapy for Progressive MS Disability Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for multiple sclerosis (MS), particularly for non-relapsing secondary progressive MS (nrSPMS) and primary progressive MS (PPMS), are inadequate in reducing disability accumulation and progression independent of relapse activity, and there is a need to mitigate drug-induced liver injury.

Innovation Solution

Administering a therapeutically effective amount of tolebrutinib or its pharmaceutically acceptable salt to patients with MS, targeting Bruton tyrosine kinase (BTK) to modulate B-cell activation and CNS-resident microglial cells, thereby reducing disability progression and lesion accumulation, and improving functional outcomes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current MS treatments are used, then relapse frequency may be reduced, but disability accumulation independent of relapse activity is not effectively prevented

Engineering Contradiction:

Improvedisability progression reductionVSAvoidfunctional outcome

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent employs tolebrutinib, a BTK inhibitor with specific pharmacological parameters optimized for crossing the blood-brain barrier and targeting CNS-resident microglial cells. This parameter change in drug mechanism (from peripheral B-cell targeting to CNS microglial modulation) effectively addresses progression independent of relapse activity while improving functional outcomes in nrSPMS and PPMS patients

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If B-cell depleting agents are administered, then immune-mediated processes are suppressed, but liver injury risks increase

Engineering Contradiction:

Improveimmune-mediated damageVSAvoiddrug-induced liver injury

Core Design Contradiction:

Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The patent uses tolebrutinib as an intermediary agent that modulates the immune response through BTK inhibition in a manner that protects against liver injury. The drug acts as a mediator between immune suppression needs and liver safety, achieving immunomodulation while maintaining liver enzyme levels within acceptable ranges through its specific mechanism of action on B-cells and microglial cells

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20260060974A1Therapeutic tyrosine kinase inhibitors for multiple sclerosis

Publication Date: 2026.03.05 PRINCIPIA BIOPHARMA INC

AI summary

This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular, Bruton tyrosine kinase (“BTK”) inhibitors, for treatment of patients with multiple sclerosis (MS).